Last reviewed · How we verify
N2O exposure
Nitrous oxide (N2O) is an inhaled anesthetic gas that depresses the central nervous system by modulating NMDA receptors and other ion channels to produce anesthesia and analgesia.
Nitrous oxide (N2O) is an inhaled anesthetic gas that depresses the central nervous system by modulating NMDA receptors and other ion channels to produce anesthesia and analgesia. Used for General anesthesia (induction and maintenance), Analgesia and anxiolysis in acute care and procedural settings, Dental anesthesia.
At a glance
| Generic name | N2O exposure |
|---|---|
| Also known as | N2O |
| Sponsor | Maisonneuve-Rosemont Hospital |
| Drug class | Inhalational anesthetic gas |
| Target | NMDA receptor (non-competitive antagonist); GABA receptors; opioid receptors |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology; Pain Management |
| Phase | FDA-approved |
Mechanism of action
N2O acts primarily as a non-competitive NMDA receptor antagonist, blocking excitatory glutamatergic neurotransmission. It also enhances inhibitory GABAergic signaling and modulates opioid and monoamine systems. These combined effects produce rapid onset anesthesia, analgesia, and anxiolysis with minimal respiratory depression at sub-anesthetic doses.
Approved indications
- General anesthesia (induction and maintenance)
- Analgesia and anxiolysis in acute care and procedural settings
- Dental anesthesia
- Emergency pain relief
Common side effects
- Nausea and vomiting
- Dizziness
- Headache
- Vitamin B12 depletion (with chronic exposure)
- Peripheral neuropathy (with chronic abuse)
Key clinical trials
- SMILE Trial - Imaging Sub-Study
- The PURI-HF (Air Purifiers on Heart Failure) Trial (NA)
- Sustained Mood Improvement With Laughing Gas Exposure (PHASE3)
- Nitrous Oxide for Late-Life Depression - PROTO-BRAIN (NA)
- Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial (PHASE4)
- Efficacy of EMONO as an add-on Therapy to Conventional Antidepressants for the Treatment of Depressive Symptoms in Nursing-home Residents With Neurocognitive Disorders: a Randomized Controlled Trial- (PHASE2)
- Virtual Reality Compared to Nitrous Oxide for Labor Analgesia (NA)
- Nitrous Oxide for the Treatment of Complex Regional Pain Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- N2O exposure CI brief — competitive landscape report
- N2O exposure updates RSS · CI watch RSS
- Maisonneuve-Rosemont Hospital portfolio CI